BioCentury
ARTICLE | Clinical News

Fosun to start clinical testing in China for Yescarta

September 7, 2018 7:33 PM UTC

China's National Medical Products Administration (NMPA) approved an application from Fosun Pharma Kite Biotechnology Co. Ltd. to begin clinical testing of Yescarta axicabtagene ciloleucel to treat recurrent and refractory large B cell lymphoma. Fosun Kite Pharma plans to begin Phase I testing "when ready."

Fosun Pharma Kite is a JV formed last year by Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196; HKEX:2196) and the Kite Pharma Inc. unit of Gilead Sciences Inc. (NASDAQ:GILD) to develop Yescarta in China (see "Kite, Fosun Deal")...

BCIQ Company Profiles

Gilead Sciences Inc.